RNA-Seq Blog Transcriptome Research & Industry News
OmniSeq CEO Mark Gardner describes why RNA-seq is the ideal marker to strike the right balance between imaging and other NGS DNA-seq approaches.
Read More »RNA-Seq – The Ideal Marker for Immuno-Oncology
OmniSeq Launches Immune Report Card – Integrates Clinical Grade RNA-Seq
OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and combination immunotherapy options for their patients. The assay ...
Read More »